Brief: CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs
02/07/2026 09:35
BRIEF-CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs July 2 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
PHARMA ENTERS COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR SIRNA DRUGS
PHARMA RETAINS RIGHTS TO ONE PCC IN CHINA
ENTERING INTO COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR DEVELOPMENT OF SIRNA DRUGS
PHARMA TO RECEIVE $30 MILLION UPFRONT, UP TO $540 MILLION DEVELOPMENT AND $1.2 BILLION SALES MILESTONES
ASTRAZENECA HAS OPTION FOR EXCLUSIVE GLOBAL OR EX-CHINA RIGHTS FOR EACH PCC PROGRAM
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines